Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Belgium / NCT06907810
Recruiting Not applicable

Study of Lipid Mediators in Chronic Postoperative Pain - LICP

NCT06907810 · tracked via the Priya Life Science Belgium tracker
Sponsor
Université Catholique de Louvain
Phase
Not applicable
Started
2025-03-12
Last updated
2025-04-02

Condition(s) studied

Breast Cancer FemalePostoperative Pain

Investigational drug(s) / intervention(s)

Blood sample + questionnaire

Blood sample + questionnaire: * blood sample before tumor surgery and at every follow-up visit * questionnaire before tumor surgery and at every follow-up visit

Study summary

This interventional prospective study aims firstly to investigate variations in lipid levels in blood samples and their potential relationship with the duration and/or intensity of post-operative pain. Secondly, it aims to investigate the activation of peripheral blood mononuclear cells and neutrophils in patient blood samples. The study will enrol women aged 18 years or older who have been newly diagnosed with primary invasive or non-invasive breast cancer requiring surgical removal of the tumour, with or without axillary surgery.

The main objectives of the study are To assess whether there is an association between circulating levels of lipid mediators and chronicity (\> 3 months) of postoperative pain after breast cancer surgery.

To assess whether circulating levels of lipid mediators can predict chronicity of postoperative pain in breast cancer surgery.

To assess the existence of an association between resected tissue levels of lipid mediators and chronicity of postoperative pain in breast cancer surgery.

To assess whether tissue levels of lipid mediators can predict chronicity of postoperative pain in breast cancer surgery.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Women older than 18 years * Newly diagnosed primary invasive or non-invasive breast cancer, requiring surgical excision of the tumor, with or without axillary surgery * Able to give informed consent Exclusion Criteria: * Men * Women aged less than 18 years * Pregnant women * History of major psychiatric disorders * Previous breast or axillary surgery, recurrent disease or detectable metastatic disease at the time of diagnosis * Unable to give informed consent

Primary outcome measure(s)

  • Pain intensity — Throughout the study, an average of 2 years
    Pain intensity will be evaluated using a standardized questionnaire completed by participants at each medical consultation.
  • Pain duration — Throughout the study, an average of 2 years
    Pain duration will be evaluated using a standardized questionnaire completed by participants at each medical consultation.
  • Lipid Mediator Levels in Blood — Throughout the study, an average of 2 years
    Lipid mediator levels will be quantified in blood samples by LC-MS methods

Trial sites (1)

FacilityCityRegionStatus
Cliniques universitaires Saint-Luc (UCLouvain) Brussels Brussels Capital Recruiting

More Université Catholique de Louvain trials in Belgium

Assessment of a New Tool to Measure Tongue Muscle Function Recruiting
Tongue Muscular Assessment in Healthy Children Recruiting
Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease Recruiting
Sex-difference in Response to Resistance Exercise and Training Enrolling by invitation
Study of Children's Well-being After the COVID-19 Pandemic in Belgian French-speaking Primary Schools Active, not recruiting

Other trials for the same condition

The Effect of Remifentanil on the Objectively Measured Pressure Pain Threshold Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06907810 on ClinicalTrials.gov ↗ ← All trials in Belgium